Search results
Results from the WOW.Com Content Network
Clinical practice guidelines recommend giving 6.8 mmol for typical EKG findings of hyperkalemia. [13] This is 10 mL of 10% calcium chloride or 30 mL of 10% calcium gluconate. [13] Though calcium chloride is more concentrated, it is caustic to the veins and should only be given through a central line. [13]
On their own this group of drugs may raise potassium levels beyond the normal range, termed hyperkalemia, which risks potentially fatal arrhythmias. Triamterene, specifically, is a potential nephrotoxin and up to half of the patients on it can have crystalluria or urinary casts.
"The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline". The Journal of Clinical Endocrinology and Metabolism. 101 (5): 1889–1916. doi: 10.1210/jc.2015-4061. PMID 26934393
Hyperkalemia (due to hypoaldosteronism) Elevated 17α-hydroxyprogesterone Classic 21-hydroxylase deficiency typically causes 17α-hydroxyprogesterone blood levels >242 nmol/L. [ medical citation needed ] (For comparison, a full-term infant at three days of age should have <3 nmol/L.
The ACTH test (also called the cosyntropin, tetracosactide, or Synacthen test) is a medical test usually requested and interpreted by endocrinologists to assess the functioning of the adrenal glands' stress response by measuring the adrenal response to adrenocorticotropic hormone (ACTH; corticotropin) or another corticotropic agent such as tetracosactide (cosyntropin, tetracosactrin; Synacthen ...
The normal range for blood concentration of 25-hydroxyvitamin D in adults is 20 to 50 nanograms per milliliter (ng/mL). Blood levels necessary to cause adverse effects in adults are thought to be greater than about 150 ng/mL, leading the Endocrine Society to suggest an upper limit for safety of 100 ng/mL. [1]
The Endocrine Society influences a wide range of policies affecting endocrine-related research and practice. The organization’s priorities include Increased funding for the National Institutes of Health (NIH), Ensuring access to adequate, affordable healthcare, Improved regulation of endocrine-disrupting chemicals (EDCs) in the United States and internationally, realigning physician payment ...
He has been director of the General Clinical Research Unit at Boston University for several years. [2] Holick serves as chair of NASA's "Human Health Countermeasures Element" Standing Review Panel, [5] chair of the Endocrine Practice Guidelines Committee for Vitamin D, [6] and editor-in-chief of the medical journal Clinical Laboratory. [7]